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1. Introduction 
Leucine-enkephalin and methionine-enkephalin 
are two pentapeptides with morphine like properties, 
naturally present in mammalian brain. They were 
first characterized by Hughes et al. [ 1 ] as H-TyrGly- 
GlyPheLeu-OH and H-TyrGlyGlyPheMet-OH 
respectively and found to behave as potent, although 
short lived opiates in a variety of pharmacological 
tests in vivo [2]. They do interact with the so-called 
opiate receptor (OpR) in vitro as evidenced by their 
ability to inhibit the binding to OpR of a variety of 
non-peptide opiate agonists and antagonists [3,4]. 
We have made use of radioactive enkephalins to 
demonstrate directly their interaction with the opiate 
receptor in vitro. It is shown in this report that both 
enkephalins bind with nearly equal affinities to one 
class of non-interacting sites in a particulate fraction 
from rat cerebrum. Binding of both enkephalins 
cannot be distinguished on the basis of its inhibition 
by non-peptide opiates such as levorphanol or 
naloxone, but is differentially affected by a variety 
of cations. These results are compared with those that 
have recently appeared in the litterature and which 
favor a multiplicity of enkephalin binding sites in 
similar preparations [2,.5,6]. 
2. Materials and methods 
2.1. Beparation of the crude mitochondrial paction 
Male Wistar rats, weighing 150-250 g were killed 
by decapitation. Their brains (minus cerebella) were 
North-Holland Publishing Company - Amsterdam 
quickly removed and processed at 0-4°C. Conditions 
are given for one cerebrum. The cerebrum was homo- 
geneized in 10 ml 0.32 M sucrose-l mM Tris-HCl, 
pH 7.4, with 10 strokes in a Potter-Elvehjem tissue 
grinder. The homogenate was centrifuged (1000 X g; 
5 min), the pellet (Pl) washed once and the combined 
supernatants (post-nuclear fraction) centrifuged at 
15 000 X g for 15 min. The resulting pellet (I?2 or 
crude mitochondrial fraction CMF) was homogeneized 
in 10 ml 1 mM Tris-HCl pH 7.4 and spun as before 
(15 000 X g, 15 min), to yield the osmotically 
shocked CMF, referred to as P2,osm. P2,osm (about 
50 mg protein) was resuspended in a final vol. 5 ml 
Tris-HCl, 50 mM, pH 7.4. 
2.2. Binding of labelled enkephalins to P2,osm 
Binding of tritiated leucine-enkephalin ( [3 H] LE) 
and tritiated methionine-enkephalin ( [3H] ME) to 
Pz,osm was studied by the method of Pert and 
Snyder [ 71 in Tris-HCl 50 mM pH 7.4 supplemented 
with 20 PM bacitracin to minimize peptide degrada- 
tion [3]. Protein concentrations, estimated by the 
method of Lowry et al. [8], were in the range 0.5-1.5 
mg/ml. Briefly: reaction mixtures (0.5 ml or 1.0 ml) 
were incubated, always in triplicate, for 12 min at 
35”C, with and without levorphanol(O.1 PM or 1 PM). 
They were then chilled down to 0°C (melting ice-bath) 
and filtered under suction through Whatman GF/B glass- 
fiber disks. Unbound or loosely bound radioactivity 
was washed away with two 10 ml portions of Tris- 
HCl 50 mM, pH 7.4, at room temperature. Retained 
radioactivity was counted with InstaGel (Packard, 
10 ml/filter) in a Intertechnique SL30 liquid scintilla- 
tion counter. 
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2.3. Chemicals 
[3.5-Tyrosyl-3H]enkephalin (LS-leucine), 45.6 Ci/ 
mmol and [3.5-tyrosyl-3H]enkephalin (L-5-methionine), 
31 .O Ci/mmol, the Radiochemical Center, Amersham. 
Dextrorphan and levorphanol, Hoffman-La Roche. 
Naloxone, Endo laboratories. 
3. Results 
3.1. Binding of [ 3H]LE and [3H]ME to P2,osm 
Binding of [3H] LE (in the range l-40 nM) and of 
[3H]ME (in the range 0.6-64 nM) to their membrane- 
associated sites in F’2,osm was studied in the absence 
(total binding) and in the presence (levorphanol 
insensitive binding) of 0.1 PM levorphanol, apotent 
opiate agonist. Levorphanol insensitive binding of the 
enkephalins increased linearly with increasing concen- 
trations of free ligand (not shown) and was considered 
non-specific. On the other hand, levorphanol sensitive 
(total minus non-specific) binding of both enkephalins 
was saturable and followed a simple Langmuir adsorp- 
tion isotherm. Scatchard representations of the data 
(fig.la and 1 b) yielded straight lines, indicating one 
single class of non-interacting binding sites for r3H] LE 
(Kd = 3.4 X 10m9 M) and for [3H]ME (Kd = 3.6 X 10m9 
M). Plateau values for both enkephalins were nearly 
identical and of the order of 0.1 pmol/mg protein, a 
value that is in good agreement with those reported 
for other radioactive opiates in similar preparations 
191. 
3.2. Inhibition of /3H/LE and [3H/ME binding by 
dextrorphan, levorphanol and naloxone 
Figure 2a shows that binding of [3H] LE and 
[3H]ME at their K, was little if any inhibited by 
dextrorphan at concentrations up to 100 nM whereas 
it was maximally inhibited (60%) in the presence of 
100 nM levorphanol. When normalized to the same 
control value, inhibition by levorphanol of the binding 
of both enkephalins followed the very same curve, 
half maximum inhibition being achieved at 5 nM. 
Assuming levorphanol and the peptides compete for 
the same site, then the dissociation constant for 
levorphanol was calculated to be 2.5 nM. Figure 2b 
shows that naloxone, an opiate antagonist, also 
inhibited [ 3H] LE and [3H] ME binding at their K,. 
Normalized inhibition curves of both peptides binding 
were superimposable, half maximum inhibition (30%) 
being achieved at 10 nM naloxone, maximum inhibi- 
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Fig.1. Scatchard representation of the levorphanol sensitive binding of (a) [ ‘H]LE (o n ), and (b) [ 3H]ME (o q ) to a particulate 
fraction from rat cerebrum. Squares and circles represent separate xperiments. 
210 
Volume 77, number 2 FEBS LETTERS May 1977 
#- 
0 10 
Ii-L 1.000 
loo 8-g-------*_ 
h, I % * \dA_ ~~~~_~~~~~~~~~~~~_~~~-------.-~~~ -8- -2- 
Fig.2. Effect of increasing concentrations of dextrorphan 
(*,o), levorphanol (A$) and naloxone (q~) on [ ‘H]LE 
(closed symbols) and [ ‘HIME (open symbols) binding at their 
Kd. Protein concentration of the incubation mixtures: 
1.2 mg X ml-‘. Control values were: 3775 f 127 cpm for 
[ ‘H]LE and 2581 f 35 cpm for [ ‘HIME. 
tion (60%) at 1 PM naloxone. Although the affinities 
of levorphanol and naloxone for the opiate receptor 
are nearly identical [9], the later was found to be 
less potent an inhibitor of enkephalin binding than 
the former. 
3.3. Effect of cations on 13HJLE and 13HJME binding 
The influence of various monovalent and divalent 
cations on the levorphanol sensitive binding of enke- 
phalins to Pa,osm was studied. Figure 3a indicates that 
binding of [3H] LE at its Kd was enhanced 40-60% 
over control by Mn*+ at concentrations in the range 
0.25-10 mM and to a lesser extent (1 O-30%) by Mg*’ 
at similar concentrations. In contrast to this, Na’ had 
an inhibitory effect: 50% inhibition at 20 mM, 80% 
at 100 mM. K’ was much less effective: 5% inhibition 
at 20 mM, 35% at 100 mM. Binding of [3H]ME 
(flg.3b) was found to be quite insensitive to Mn*+ 
and Mg*’ (up to 10 mM) and K’ (up to 100 mM), but 
was inhibited by Na+, although not as much, under 
similar conditions as [3H] LE: 20% (versus 50%) at 
20 mM, 60% (versus 80%) at 100 mM. % 
4. Discussion 
The present study has shown that leucine- and 
methionine-enkephalin bind with a high affinity 
(& values of 3.4 nM and 3.6 nM, respectively) to 
one single class of non-interacting, membrane-bound 
sites in a particulate fraction of rat cerebrum. Recent 
reports, however, favor a multiplicity of enkephalin 
binding sites in similar preparations. According to 
Simantov and Snyder [3], Scatchard analysis of 
[3H] ME binding to the opiate receptor reveals two 
distinct linear components with &+&es of 0.64 nM 
and 2.6 nM. Morin et al. [5] describe binding of 
[3H]ME to a particulate fraction from rat brain on the 
basis of two independent binding sites with Kd-values 
of 2.1 nM and 53 nM. Finally, Audigier et al. [6] 
using [3H] LE present evidence for two saturable 
components with Kd-values of 2.7 nM and 30 nM, the 
low affinity component being insensitive to non- 
peptide opiates [lo]. It must be pointed out that in 
contrast to the present study and that of Simantov 
and Snyder, Morin et al. and Audigier et al. have not 
selected as specific for enkephalins those sites that 
are levorphanol sensitive. Then their low affinity 
components might represeut specific recognition sites 
not carried by the opiate receptor but by other 
membrane bound molecules involved in the synthesis, 
degradation, transport or secretion of the penta- 
peptides, a situation encountered before in other 
systems [ 1 l] . 
Binding of enkephalins to the opiate receptor 
(OpR) is not inhibited by 100 nM dextrorphan, but is 
maximally inhibited by 100 nM levorphanol. This 
result is consistent with the fact that dextrorphan is 
four orders of magnitude less potent than levorphanol 
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Fig.3. Effect of increasing concentrations of Mn” (*,o), Mga+ (a,~), K+ (~,a) and Na+ (*,O) on the levorphanol sensitive binding of 
[‘HI LE (a) (closed symbols) and [‘HI ME (b) (open symbols) at their Kd to a particular fraction from rat cerebrum. Protein 
concentrations of the incubation mixtures: 1.2 mg X ml-‘. Control values were: 1623 f 104 cpm for [ ‘HJLE and 1523 f 363 cpm 
for [ ‘HIME. 
in antagonizing binding of [‘Hlnaloxone to OpR [9]. 
Naloxone, an opiate antagonist, although it has an 
affinity nearly equal to that of levorphanol for OpR 
was less efficient than the later in inhibiting enkephalin 
binding. This is best explained by the fact that recogni- 
tion sites for opiate agonists and antagonists are, at 
least partially, distinct: they can be discriminated upon 
treatment with enzymes [ 121 and protein-modifying 
agents [ 131. 
Binding of enkephalin to OpR is differentially 
affected by a variety of cations. t3H] LE-Binding at 
its K, is enhanced by Mn2+ and Mg2+ and inhibited 
by Na’ and K’: this is typically an opiate agonist 
response [14,15]. On the other hand, t3H]ME- 
binding at its Kd is quite insensitive to Mn’+, Mg2+ 
and K’ and inhibited by Na+: methionine-enkephalin 
behaves like a mixed agonist-antagonist. These con- 
clusions agree well with those of Simantov and 
Snyder [3] . Although we have not yet investigated 
this point, cations are likely to act upon the affinity 
of the pentapeptides for OpR as it has been shown 
to be the case for the opiate antagonists naltrexone 
[16] and naloxone [17]. 
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